Skip to main content

Table 2 Subjects with AD, PD, DLB, ILBD and with a normal neuropathological examination exhibited α-synuclein deposits in pancreatic β cells

From: Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein

Groups Pα-synuclein Cleaved α-synuclein Nitrated α-synuclein
Subjects with a normal neuropathological examination 5/27 (19%)* 13/27 (48%) 4/27 (15%)
Subjects with a normal neuropathological examination and T2DM 6/13 (68%)* 18/19 (95%) 7/19 (37%)
AD with low neuropathologic change 11/28 (39%) 23/28 (82%) 7/28 (25%)
AD with intermediate neuropathologic change 13/26 (50%) 25/26 (96%) 15/26 (58%)
AD with high neuropathologic change 6/8 (75%) 8/8 (100) 4/8(50%)
Incidental Lewy body disease 5/8 (63%)* 8/8 (100%) 3/8 (38%)
Parkinson's disease 9/10 (90%)* 10/10 (100%) 6/10 (60%)
Dementia with Lewy bodies 11/12 (91%)* 12/12 (100%) 6/12 (50%)
  1. The data are represented as n (%). AD, Alzheimer disease; PD, Parkinson’s disease; DLB, dementia with Lewy bodies; ILBD, incidental Lewy body disease; T2DM, type two diabetes mellitus. *These results had been previously published in Martinez-Valbuena, et al. 2018 and have been added in this table to facilitate comparisons between groups